Introduction
The Cochrane Injuries Group reviewed randomized controlled trials on the use of HSA in hypovolemia, burns, and hypoproteinemia in 2004 [1] . There was no evidence for a benefit of HSA compared with patients treated with cristalloids [1] . A recent post hoc analysis of the Saline versus Albumin Fluid Evaluation study in patients with severe traumatic brain injury even reported an ϳ1.9-fold increase in mortality upon infusion of HSA compared with saline [2, 3] . There is ample evidence that infusion of protein containing infusion solutions can cause an increase in inflammatory markers: Administration of HSA in vitro and in vivo led to increased expression of adhesion molecules such as VCAM-1 and ICAM-1, which are controlled partly by NF-B [4 -7] . The degree of ICAM expression in vitro varied between different batches of HSA [7] . In patients with sepsis, HSA infusion caused a lower partial pressure of oxygen/fraction of inspired oxygen and a tendency toward worsened outcome [4] . A retrospective study on patients with minimal change glomerulonephritis revealed that patients treated with HSA had an aggravation of disease with more frequent relapse and delay of remission [8] . The authors speculated that this was possibly a result of a damage of glomerular epithelium induced by HSA infusion [8] . In addition to HSA, other protein-containing solutions led to relevant side-effects. For instance, cases of venous thrombosis have been linked to Ig infusion [9, 10] . The incidence of arterial as well as venous thrombosis upon Ig infusion is estimated at 3% [9] . Many pathophysiological mechanisms for this have been discussed, including altered levels of coagulation factors or platelet aggregability [10] .
These clinical observations indicate that HSA or Ig preparations might contain an activity leading to a proinflammatory and procoagulant environment. This activity seems to be present in different protein preparations and therefore, not to be dependent on the protein itself but potentially on posttranscriptional, possibly manufacturing-induced changes in the protein. Quality control of protein-containing preparations for i.v. use in critically ill or hemophilic patients is established with respect to the purity and the sterility of the solution. Infusion solutions are screened routinely for infectious agents including viruses and bacteria but not for post-translational modification of the proteins themselves. However, inflammatory reactions can be induced by post-translationally modified proteins formed by nonenzymatic glycation reactions [11] [12] [13] [14] [15] .
Glucose and other reducing carbohydrates used in some protein-containing preparations as stabilizers react with N-terminal residues and/or -amino groups of lysine in proteins generating irreversible AGEs. CML, one of the more abundant AGE structures identified to date, is a product of glycoxidation (combined nonenzymatic glycation and oxidation) and lipid peroxidation [16 -19] . CML-modified proteins have been shown to be critically involved in "inflammatory reactions". Upon binding to RAGE, ligands activate the proinflammatory transcription factor NF-B, proinflammatory gene expression, induction of local inflammation, neointimal expansion in arterial restenosis, and atherosclerosis [14, 18, 20 -24] . Ligation of CML-modified proteins to RAGE and subsequent activation of NF-B have been demonstrated to up-regulate cytokines, leukocyte adhesion molecules, clotting factors, and vasoconstrictors in a variety of cell types including mononuclear and endothelial cells [25] [26] [27] . Other post-translational protein modifications such as pentosidine, pyrraline, and CEL have also been connected to chronic disease and aging [22, 28 -33] . In this context, peritoneal dialysis fluids containing glucose degradation products have been shown to lead to an increased formation of AGEs that mediate peritoneal damage via activation of RAGE [34] . A pilot study about post-translational modification of human albumin solutions focusing on cysteinylation and nitrosylation showed varying degrees of modification [35] .
In view of these data, AGE modification might change the biological activity of stabilizing proteins in infusion solutions from the osmoregulating desired to a proinflammatory activity. This could be of importance for licensed drugs such as HSA, Ig, or coagulation factors, frequently given to critically ill patients. These considerations prompted us to study the presence of AGEs and their functional significance in commercially available infusion solutions.
MATERIALS AND METHODS

Material
DMEM (4.500 mg/l glucose), RPMI 1648, HEPES buffer solution, L-glutamine, penicillin-streptomycin mixture, and PBS (pH 7.4) were from BioWhittaker (Walkerville, MD, USA). FCS was from Gibco/BRL (Dreieich, Germany). [␥-
32 P]ATP (3000 Ci/mmol at 10 mCi/ml), L-methionine (Ͼ1000 Ci/mmol at 10 mCi/ml), Hybond-N-nylonfilter, ECL-nitrocellulose membranes, ECL detection reagents, and Hyperfilm X-ray films were obtained from Amersham (Freiburg, Germany). Poly dI/dC and oligo(dt)
were from Pharmacia (Freiburg, Germany). E. Schleicher (University of Tübingen, Germany) provided CML antibodies, pan-AGE antibodies were obtained from Biologo (Kronshagen, Germany), and both have been described previously [29, 36] . Anti-p65, anti-p50, anti-cRel, and anti-RelB antibodies and protein A/G PLUS-agarose were obtained from Santa Cruz (Heidelberg, Germany). Effectene transfection reagent was obtained from Qiagen (Hilden, Germany). Commercially available HSA, Ig, and factor VIII preparations licensed for i.v. use were purchased from the respective dispensaries of the University of Tübingen and University of Heidelberg Hospitals (Germany). Manufacturers of the HSA, factor VIII, and Ig preparations were Octapharma (Langenfeld, Germany), Centeon Pharma (Marburg, Germany), Biotest (Dreieich, Germany), Behring (Marburg, Germany), Pharma Dessau (Dessau, Germany), DRK Blutspendedienst (German Red Cross, Berlin, Germany), Bayer AG (Leverkusen, Germany), and Baxter (Heidelberg, Germany). The preparations were stored at 4°C and used for cell incubation experiments before date of expiry. Aliquots were frozen at -80°C for experiments performed after the expiry date for clinical use.
RAGE؊/؊ mice
RAGEϪ/Ϫ mice were constructed on the SVEV129ϫC57BL/6 (129/B6) background before backcrossed Ͼ10 times onto the C57BL/6 [23, 37, 38] . The mice are viable and display normal reproductive fitness. Mice were housed individually with a 12-h/12-h light/dark cycle and free access to food and water. The Animal Care and Use Committee at the Regierungspräsidium Karlsruhe (Germany) approved procedures in this study.
Quantification of AGE modifications in protein solutions
Western blot analysis for CML and pan-AGE was performed as described previously in detail [20] . We used 7 g protein HSA, Ig, or factor VIII for analysis. Signals obtained were quantified by densitometry and are given as relative CML and pan-AGE units. Mean variability of arbitrary unit ratios between different samples in serial measurements was calculated below 20%. For chemical analyses of AGEs, CML and CEL were measured in ϳ2 mg protein by GC/MS; pentosidine was measured in a separate sample, ϳ3 mg protein, by HPLC, all as described previously [39] . The samples were analyzed in duplicate in a single batch, and the variation between duplicates was generally Յ10%. Duplicate quality control samples with a comparable level of CML were included with the batch, and values obtained were within the accepted range.
Cell culture and transfection experiments
BAEC were grown in DMEM supplemented with 10% FCS, glutamine, and penicillin/streptomycin mixture (all BioWhittaker) to confluency and incubated with different concentrations of HSA solution. All HSA solutions were screened for LPS contamination using the Limulus assay (Sigma, Deisenhofen, Germany). BAEC were grown in DMEM medium containing 10% FCS to 70% confluency before 1.4 g plasmid DNA/ml medium was transfected for 42 h using Effectene (Qiagen) in the absence or presence of 800 nM HSA containing infusion solutions [25] . To monitor NF-B-dependent gene expression, defined TF plasmids were used [40] , which spanned the TF-core promoter consisting of two AP-1 and the TF-specific NF-B binding site (PL-4), the TF-specific NF-B binding site (PL-21), or the TF-promoter sequence, in which AP-1 and NF-B binding sites had been deleted (PL-6) [40, 41] To correct for variability in transfection efficiency, 0.15 g pSV-␤-gal plasmid/ml medium was included. Luciferase activity and ␤-gal activity were determined for each sample, and the ratio of luciferase activity to ␤-gal activity served as a measure for normalized luciferase activity. Each experiment was performed in triplicate [41] .
EMSA
Nuclear proteins were harvested and assayed for NF-B binding activity as described previously [20] . In brief, cells were washed in PBS, resuspended in 200 l cold buffer A (10 mM HEPES-KOH, pH 7.9, at 4°C, 1.5 mM MgCl 2 , 10 mM KCl, 0.5 mM DTT, 0.2 mM PMSF), vortexed for 10 s, and incubated on ice for 10 min. Samples were centrifuged at highest speed for 2 min in a table centrifuge, and the supernatant was discarded. The pellet was resuspended in 100 l cold buffer C (20 mM HEPES-KOH, pH 7.9, 25% glycerol, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT, 0.2 mM PMSF) and incubated on ice for 20 min. After centrifugation (2 min, 4°C, highest speed), the supernatant was quick-frozen at -80°C. Protein concentration was determined using a colorimetric assay based on Bradford. Binding of NF-B to 1 ng radiolabeled NF-B consensus oligonucleotides (5Ј-AGT TGAGGG GAC TTT CCC AGG C-3Ј) was performed for 20 min at room temperature in 10 mM HEPES, pH 7.5, 0.5 mM EDTA, 100 mM KCl, 2 mM DTT, 2% glycerol, 4% Ficoll, 0.25% Nonidet P-40, 1 mg/ml BSA, and 0.1 mg/ml poly dI/dC. Protein DNA complexes were separated on 5% native polyacrylamide gels containing 3.25% glycerol and 0.5ϫ Tris-boric acid-EDTA buffer. Specificity of binding was ascertained by competition with a 160-fold molar excess of unlabeled consensus oligonucleotides and in supershift experiments using antibodies for NF-B subunits (p50, p65, cRel, RelB, p52) [20] .
One-stage clotting assay
One-stage clotting assay for determination of TF activity was performed as described [42] . After washing, cells were removed by scraping in barbital buffer, pH 7.6, collected by centrifugation for 5 min at 1000 rpm, and resuspended in 100 l of the same buffer. After addition of 100 l citrated bovine plasma, 100 l citrated bovine plasma, and 100 l 25 mM CaCl 2 solution (Behring), the samples were incubated at 37°C. The time from addition of CaCl 2 to the first defined fibrin strand was determined. TF activity was calculated by comparing the measured clotting time with a standard curve made with known amounts of TF as published previously [42] . The measured amount of TF was expressed as picograms of TF/10 6 cells Ϯ sd. All experiments were performed at least three times, and each experiment was done in triplicate.
CLP
CLP was performed in 10-to 12-week-old male C57Bl6 and RAGEϪ/Ϫ mice as described previously in detail [23] . In brief, mice were anesthetized by i.p. administration of 75 mg/kg Ketanest (Parke-Davis, Berlin, Germany) and 16 mg/kg Rompun (Bayer AG) in 0.2 ml sterile saline (Braun AG, Melsung, Germany). The cecum was exposed through a 1.0-to 1.5-cm abdominal midline incision and subjected to ligation 6 mm from the cecal tip, followed by a single puncture with a 6, 23 needle. A small amount of stool was expelled to ensure patency. The cecum was replaced, and the incision was closed using 5/0 Prolene thread (Ethicon, Norderstedt, Germany). No antibiotics were administered. Mice were treated with 1.5 mg/g body weight of the respective HSA solution, a dose that was shown previously to be effective in patients with peritonitis [43] . Two shots of the respective HSA solution, a chemically modified CML albumin [15, 20] and 0.9% saline serving as positive and negative controls, were injected i.p. in a total volume of 100 l. Injections were administered immediately and 6 h after surgery. Researchers were "blinded" with respect to the treatment group. Survival after CLP was assessed four to six times/day for at least 7 days. For histopathology and immunohistology, organs were harvested 24 h after CLP. Tissues and organs were fixed in 4% formalin, and sections 5 m in thickness were cut and were stained with H&E as well as activated NF-Bp65 antibodies (Boehringer Mannheim, Mannheim, Germany) according to standard protocols. Infiltrating inflammatory cells in the peritoneum were counted using a microscope. The animal care authorities (Regierungspräsidium Karlsruhe) approved all CLP experiments.
Statistical procedures
Statistical relevance of the data on survival of mice in the CLP experiments is shown as given by the log rank test using StatView software (SAS Institute, Cary, NC, USA). In vitro experiments were analyzed by Student's ttest, ANOVA, and calculation of the Pearsons correlation coefficient using SPSS software, Version 16.0 (SPSS, Chicago, IL, USA). All data are given as mean Ϯ sd.
RESULTS
The post-translational modification of commercially available protein-containing infusion solutions was analyzed by several methods. When preparations of HSA, Ig, and factor VIII solutions were assayed for the presence of CML-and AGE-modified proteins using Western blot analysis, these post-translational modifications were detected in almost all preparations. The level of modification was not company-specific, differed between batches from the same company (data not shown), and ranged from 4.2 to 12.1 relative pan-AGE units and 7.4 to 30.5 relative CML units for HSA (Fig. 1, A and B) . The protein modifications CML, CEL, and pentosidine were also quan- tified by GC/MS as described previously [39] . The degree of modification for CML ranged from 0.13 mmol/mol lysine (A4) to 0.36 mmol/mol lysine (A6) and 91 to 252 pmol CML/mg HSA (Fig. 1C ) and correlated well with the antigen detection in the CML-Western blot (Rϭ0.8). CML modification in nine different Ig preparations ranged from 0 to 9.3 relative units (Fig. 1D) . The degree of CEL modification detected in HSA solutions ranged from 0.015 (A3) to 0.029 (A2) mmol/mol lysine, and pentosidine modification ranged from 1.37 (A3) to 2.08 (A1) mol/mol lysine (data not shown). In both assays, the HSA solution called "A4" showed the lowest and "A6" the highest degree of AGE modification. Hence, these preparations were used for further experiments in vitro and in vivo.
Highly AGE-modified HSA infusion solutions increase mortality in CLP
To study the relevance of increased AGE formation in vivo, wild-type mice were treated with a clinically relevant dose (1.5 mg/g body weight) [43] of the low-modified solution A4 and the highly AGE-modified HSA infusion A6, as well with saline 0.9% or chemically modified CML-albumin solution serving as negative and positive controls, respectively. Compared with injection of 0.9% saline, the low-AGE solution A4 did not influence the CLP survival rate of 60% observed in wild-type mice undergoing CLP (Fig. 2) . These survival rates correspond to data published previously for control treatments in murine CLP [44, 45] . In contrast, injection of CML-albumin decreased the survival rate to 30% (Fig. 2) . All mice injected with the highly AGEmodified solution A6 died within 60 h after CLP (Fig. 2) .
Effects of AGE-modified HSA infusion solutions on cellular NF-B activation
As immunohistological staining for activated NF-Bp65 in serosa of mice treated with HSA solution A6 demonstrated an increased activation and nuclear translocation of NF-Bp65 in mononuclear cells and endothelial cells 24 h after CLP (Fig.  3A) , we hypothesized that AGE-dependent NF-B activation might be one mechanism underlying increased lethality upon infusion of highly modified HSA solution. One unique feature of RAGE-mediated NF-B activation is the prolonged time course, which appears to overwhelm endogenous autoregulatory feedback inhibition loops mediated by IBs [20] . Consistently, ligation of RAGE does not only result in transient NF-B activation but replaces endogenous negative-feedback pathways, those responsible for returning cellular behavior to homeostasis, by an upwardly spiraling cycle of cellular perturbation [20] . To confirm a RAGE involvement in HSA-mediated NF-B activation, BAEC were incubated with 800 nM of the different HSA preparations for 5 days, before sustained NF-B binding activity to a NF-B consensus motif was monitored in EMSA [20] . These experiments demonstrated that the degree of NF-B binding activity varied between different HSA infusion solutions depending on the extent of modification. Incubation with low AGE-modified A4 resulted in only moderate induction of NF-B binding activity, and HSA preparation A6 showed highly increased NF-B binding activity (Fig. 3B) .
Supershift experiments demonstrated that the binding complex induced by all substances was formed by the NF-B subunits p50, p65, and cRel and to a lesser degree, by RelB (Fig.  3C ), indicating that increased activation rather than a shift in composition accounted for the differences in activation.
To further study the functional relevance of NF-B activation, we studied the modulation of NF-B-dependent gene expression by the different HSA solutions. TF is the major cellular initiator of blood coagulation and a marker of inflammation [46] that critically contributes to the outcome of septicemia [47] [48] [49] , and its expression is controlled partly by NF-B [25, 40] . TF activity was first studied in one-stage clotting assays after incubating BAEC with 800 nM HSA for 5 days. Consistent with the results for NF-B activation, HSA preparation A4 (containing 0.13 mmol CML/mol lysine) induced TF expression to a much lower degree than HSA preparation A6 (containing 0.36 mmol CML/mol lysine; Fig. 3D ). Transient transfection experiments using TF promoter constructs confirmed that TF expression was dependent on NF-B activation. The "low-AGE" HSA preparation A4 had a less-prominent effect on TF expression of the transgene than the "high-AGE" preparation A6. Consistent with previous reports, induction of TF was highest when plasmids spanning AP-1 sites and the NF-B site of the TF promoter were transfected (Fig. 3E) . However, constructs containing the TF-specific NF-B binding [15, 20] or 0.9% saline in a total volume of 100 l. All mice treated with clinically relevant doses (1.5 g/kg) of the highly CML-modified human albumin A6 died within 60 h, and mice treated with saline or the low-modified A4 show a 60% survival of CLP, as was shown previously for control treatments [44, 45] . Mice treated with chemically modified CML-albumin serving as a positive control show a 30% survival after CLP. Statistics as given by log rank test versus control treatment with NaCl (nϭ7 mice/treatment group). Overall P value for model is 0.02. *, Statistically significant according to Bonferroni's correction for multiple testing.
site only were still highly inducible by CML-containing solutions such as the CML-control preparation (ϳ0.53 mmol CML/mol lysine; black bar) or HSA solution A6 (open bars). TF expression in response to the low-AGE/low-CML preparation A4, however, was weaker under all conditions tested. TF induction was abolished completely in promoter constructs lacking these transcription factor-binding sites. This corresponds to previous reports demonstrating that TF expression is mediated by a concerted action of AP-1 and NF-B and strongly dependent on the presence of NF-B [25, 40] .
Consistently, the degree of CML and pan-AGE modification determined by Western blot analysis correlated positively with the extent of NF-B binding activity induced by the various solutions. This was significant for pan-AGE (Rϭ0.8; PϽ0.05; Fig. 4A ) and CML (Rϭ0.9; PϽ0.01; Fig. 4B ). The correlation of NF-B activation and CML concentration was indicative of CML-modified proteins being one major NF-B-activating substance in the HSA solutions [50] . Consistently, chemical analysis (GC/MS), which allows determination of the degree of CML modification/mol lysine residue in HSA, confirmed that the ex- 
RAGE؊/؊ mice are protected from the HSA-induced decrease in CLP survival
As it was shown previously that CML-modified proteins cause sustained NF-B activation by ligation to its receptor RAGE [20] , and RAGE and RAGE-dependent, sustained NF-B activation is regarded as a critical mediator of mortality in septicemia [23, 51, 52] , we determined the effects of the AGE-modified HSA solutions on CLP survival and infiltration of mononuclear cells in RAGEϪ/Ϫ mice. In contrast to wild-type mice (Fig. 2) , RAGEϪ/Ϫ mice were largely protected from the deleterious effects of A6 and CML injection (Fig. 5A) . Although the wild-type mice showed markedly increased infiltration of mononuclear cells into the serosa upon treatment with A6 (Fig. 5B) , no differences were observed in the saline-treated and A6-treated RAGEϪ/Ϫ mice (Fig. 5C) . Consistent with previous reports indicating a mild proinflammatory phenoytpe in RAGEϪ/Ϫ mice [38, 50, 53] , however, the basal infiltration of mononuclear cells was higher in RAGEϪ/Ϫ mice when compared with RAGE-bearing wild-type mice.
DISCUSSION
Although all preparations studied were licensed for i.v. use and free of endotoxin, they contained AGE-and in particular, CML-modified proteins. The degree of modification differed between manufacturers and also within batches from the same company (not shown). The CML content ranged from ϳ125 pmol/mg in HSA preparation A4 to ϳ250 pmol/mg in solution A6. The concentration of CML-modified protein in A4 therefore relates to that found in serum of healthy volunteers, previously shown to be at ϳ76 pmol/mg serum protein [54] . In contrast, the CML modification in HSA A6 is close to the situation found, for example, in uremic dialysis patients, in which CML modification is enhanced markedly [54] . The significance for the clinical situation becomes evident considering the following calculation: In a 70-kg person, infusion of 250 ml 20% HSA would lead to a concentration of ϳ140 M HSA containing ϳ700 nmol CML modifications. This corresponds to a concentration-saturating RAGE, as half-maximal binding of AGE-modified albumin to RAGE has been reported at ϳ100 nM [18] . Under this condition, tissue deposition of AGE-modified HSA [55, 56] might therefore become an additional pathogenic factor. Although it is not known yet whether AGE modifications reduce or increase the half-life of HSA, recent studies provide evidence for a glycation-mediated, increased stability of different substrates toward enzymatic degradation [57, 58] . The latter implies that the half-life of AGEmodified HSA might even surpass the half-life of unmodified HSA, known to ϳ19 days, and supports the potential importance of glycated HSA as an inducing and amplifying inflammatory stimulus.
The data presented indicate that the CML modifications in HSA have the potential to induce and sustain the up-regulation of NF-B-dependent proinflammatory and procoagulant pathways in vitro and in vivo. This could define CML-modified proteins as a novel noninfectious proinflammatory "contaminant" of protein infusion solutions licensed for i.v. use. These findings are consistent with earlier observations showing increased expression of NF-B-controlled cellular adhesion molecules following treatment of endothelial cells in vitro and critically ill patients with different HSA preparations [4 -7] . Interestingly, other non-RAGE-binding AGE adducts such as pentosidine or CEL did not correlate with the NF-B-activating activity found upon incubation of BAEC with HSA (not shown). The RAGE-dependent activation of NF-B by CMLmodified proteins reported previously [18] therefore seems to be the predominant mechanism for the sustained NF-B activation [20] observed (Fig. 3, A-C) . In the CLP experiments, wild-type mice treated with HSA A6 died within 60 h after CLP, and mice treated with chemically modified CML albumin showed a survival rate of 30%. Furthermore, RAGEϪ/Ϫ mice were protected from CML-mediated lethality and showed only a nonsignificantly increased mortality in response to HSA A6 (Fig. 5A) . Therefore, A6 might contain additional substances, possibly small glucose degradation products, reactive oxygen species, or other oxidation products [19, 34, 35, 59 ] that add to the deleterious effects of the highly AGE-modified solution A6.
HSA solutions are generally obtained from pooled healthy donors, making it unlikely that the differences observed between manufacturers and batches are a result of the degree of CML-modified protein in individual donors. For healthy donors, the CML concentration should correspond to the 76-pmol/mg serum protein reported previously [54] . Thus, the differences in CML modification we observed most likely result from conditions during the manufacturing process rather than differences in plasma CML modification between individual donors. The manufacturing processes leading to enhanced AGE and CML modification have yet to be identified. The most commonly used method of HSA isolation from human plasma is alcohol-fractionating, first described in 1948 by Cohn, which has since been modified using different alcohols, temperatures, pH, and salt concentrations [60, 61] . Independent of the isolation method, the HSA solutions are heated to a temperature ϳ60°C for inactivation of bacteria and viruses.
In addition to the use of reducing stabilizers, heating thus could catalyze the formation of AGEs. Nevertheless, the approximate tenfold differences in AGE content found in this study indicate that it should be possible to prepare protein solutions for clinical use without significant amounts of AGEmodified proteins.
Data concerning late complications following regular infusion of protein-containing infusion solutions are not available, yet acute renal failure has been linked to infusion of sucrosecontaining Ig preparations in diabetic patients [62] . Although sucrose is a nonreducing disaccharide, the manufacturing process may generate reducing carbohydrates (for example, by changes in pH), which can form AGEs. Consistently, sucrosefree Ig preparations have been used successfully in patients with previous acute renal failure following infusion of sucrosecontaining Ig solution [63] . Our data clearly demonstrate that highly AGE-modified protein solutions boost inflammation and lethality in CLP in a RAGE-dependent manner. As expression of RAGE and RAGE-dependent NF-B activation was shown recently to play a central role in experimental [23, 52] and clinical [51] sepsis and that transmigration of neutrophils across the intestinal epithelium is influenced by RAGE [64] , it seems suggestive that ligands such as CML-modified proteins known to induce RAGE-dependent NF-B activation could boost inflammatory reactions in critically ill or immunodeficient patients treated with AGE-modified infusion solutions. In conclusion, this is the first study describing post-translational modifications on HSA as influence factors on survival in an experimental model of peritonitis and sepsis. Clinical studies comparing the use of "high-CML/AGE"-and "low-CML/ AGE"-modified protein containing infusion preparations are needed to evaluate the clinical significance of the data presented here. The detection of post-translational protein modifications changing the biological activity from the desired to a proinflammatory and procoagulatory action could become part of quality control for protein preparations licensed and on the market for i.v. use.
